Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, positioning Ethereum (ETH) as a strategic reserve asset [2][5] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions and explore the integration of crypto assets with real-world assets (RWA) [5][10] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [5][10] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [8][9] - The ivd.xyz exchange is the first Web3 exchange focused on medical innovation drug RWA, combining centralized and decentralized exchange features to support cross-chain trading [8][9] - The company's downward protection mechanisms include an ATM mechanism, a priority structure, RWA price buyback commitments, and a clinical VC safety net, providing comprehensive protection for investors [9] Group 3 - The Ethereum Vault strategy opens up a potential market capitalization growth space of over 100 billion HKD, drawing parallels with MicroStrategy's Bitcoin strategy, which saw an 80-fold increase in market value [10] - The company’s current market capitalization exceeds 13 billion HKD, indicating significant growth potential compared to MicroStrategy and Metaplanet [10] - The strategy aligns with the Hong Kong Monetary Authority's Ensemble project and China's innovation drug export strategy, aiming to lower financing costs and accelerate technology transfer [11]
带“主动生币功能”的微策略！华检医疗引爆以太坊金库革命